SPL Industries, Brawn Biotech, Rishi Techtex Post Profits Amidst Simbhaoli Sugars Insolvency

SPL Industries reported a net profit of ₹3.96 crore on revenues of ₹29.07 crore for the quarter ended March 31, 2026. Brawn Biotech posted a net profit of ₹0.58 crore on revenues of ₹2.16 crore. Rishi Techtex reported ₹0.47 crore net profit on ₹42.68 crore revenue for the same period.

Reader Takeaway: Profitable quarters for SPL, Brawn, Rishi contrast with Simbhaoli's critical insolvency situation.

What just happened

SPL Industries Ltd., Brawn Biotech, and Rishi Techtex have disclosed their financial results for the quarter ending March 31, 2026. Simultaneously, Simbhaoli Sugars Limited released its results for the quarter ending December 31, 2025.

Why this matters

For SPL Industries, Brawn Biotech, and Rishi Techtex, the results indicate current profitability and operational performance. For Simbhaoli Sugars, the update highlights its ongoing severe financial distress and insolvency proceedings.

The backstory

Simbhaoli Sugars Limited is currently undergoing a Corporate Insolvency Resolution Process (CIRP), admitted by the National Company Law Tribunal (NCLT) Allahabad on July 11, 2024. An Interim Resolution Professional (IRP) has taken charge of the company's management.

What changes now

Investors can review the financial health of SPL Industries, Brawn Biotech, and Rishi Techtex based on their latest audited results. For Simbhaoli Sugars, the focus remains on the progression of the CIRP.

Risks to watch

The primary risk is associated with Simbhaoli Sugars, where the CIRP poses significant uncertainty regarding its future operations and stakeholder value. The other companies' risks would be standard business and market risks.

Peer comparison

SPL Industries, Brawn Biotech, and Rishi Techtex are reporting profits, while Simbhaoli Sugars is in a critical insolvency phase, indicating vastly different financial standings.

Context metrics (time-bound)

• SPL Industries: Q4 FY2026 Revenue ₹29.07 crore, Net Profit ₹3.96 crore.
• Brawn Biotech: Q4 FY2026 Revenue ₹2.16 crore, Net Profit ₹0.58 crore.
• Rishi Techtex: Q4 FY2026 Revenue ₹42.68 crore, Net Profit ₹0.47 crore.
• Simbhaoli Sugars: Q3 FY2026 Revenue ₹209.39 crore, Net Loss ₹-14.21 crore.

What to track next

Investors should monitor future financial disclosures from SPL Industries, Brawn Biotech, and Rishi Techtex. For Simbhaoli Sugars, updates on the CIRP proceedings and potential resolutions will be crucial.